799,426 Shares in Crocs, Inc. $CROX Bought by Patient Capital Management LLC

Patient Capital Management LLC purchased a new stake in Crocs, Inc. (NASDAQ:CROX) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 799,426 shares of the textile maker’s stock, valued at approximately $96,443,000. Crocs accounts for about 3.2% of Patient Capital Management LLC’s investment portfolio, making the stock its 15th biggest holding. Patient Capital Management LLC owned about 1.67% of Crocs at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Crocs by 159.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 746 shares of the textile maker’s stock valued at $79,000 after buying an additional 459 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Crocs by 4.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 211,305 shares of the textile maker’s stock worth $22,441,000 after acquiring an additional 8,331 shares during the last quarter. EverSource Wealth Advisors LLC raised its holdings in shares of Crocs by 278.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 862 shares of the textile maker’s stock worth $87,000 after acquiring an additional 634 shares during the last quarter. First Trust Advisors LP lifted its position in Crocs by 14.3% in the 2nd quarter. First Trust Advisors LP now owns 112,217 shares of the textile maker’s stock valued at $11,365,000 after acquiring an additional 14,067 shares in the last quarter. Finally, Marshall Wace LLP bought a new position in Crocs in the 2nd quarter valued at about $6,290,000. Institutional investors and hedge funds own 93.44% of the company’s stock.

Insider Transactions at Crocs

In other Crocs news, CEO Andrew Rees sold 19,072 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $138.91, for a total transaction of $2,649,291.52. Following the sale, the chief executive officer owned 713,293 shares in the company, valued at $99,083,530.63. This represents a 2.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Over the last quarter, insiders have sold 62,688 shares of company stock worth $8,014,859. Insiders own 3.10% of the company’s stock.

Crocs Price Performance

CROX stock opened at $122.11 on Monday. The company has a debt-to-equity ratio of 0.94, a quick ratio of 0.96 and a current ratio of 1.49. The company has a market capitalization of $5.85 billion, a price-to-earnings ratio of 10.55, a PEG ratio of 1.02 and a beta of 1.53. Crocs, Inc. has a fifty-two week low of $73.21 and a fifty-two week high of $141.28. The stock has a fifty day moving average of $129.45 and a 200-day moving average of $108.52.

Crocs (NASDAQ:CROX) last announced its quarterly earnings results on Thursday, July 30th. The textile maker reported $4.55 EPS for the quarter, beating analysts’ consensus estimates of $4.35 by $0.20. The company had revenue of $1.18 billion for the quarter, compared to analysts’ expectations of $1.15 billion. Crocs had a net margin of 14.64% and a return on equity of 47.75%. Crocs’s revenue was up 2.6% compared to the same quarter last year. During the same period in the prior year, the company posted ($8.82) EPS. Crocs has set its FY 2026 guidance at 13.700-14.000 EPS and its Q3 2026 guidance at 3.200-3.300 EPS. As a group, equities research analysts predict that Crocs, Inc. will post 13.95 earnings per share for the current year.

Wall Street Analysts Forecast Growth

CROX has been the subject of a number of recent research reports. UBS Group boosted their price objective on Crocs from $107.00 to $120.00 and gave the stock a “neutral” rating in a report on Friday, July 31st. Piper Sandler restated an “overweight” rating on shares of Crocs in a report on Friday, July 31st. Monness Crespi & Hardt lifted their target price on Crocs from $130.00 to $160.00 and gave the company a “buy” rating in a research report on Friday, July 31st. Scotiabank began coverage on Crocs in a report on Monday, June 8th. They set an “outperform” rating for the company. Finally, Seaport Research Partners increased their price target on Crocs from $135.00 to $160.00 and gave the company a “buy” rating in a research report on Monday, July 20th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Crocs currently has an average rating of “Moderate Buy” and an average target price of $139.10.

Crocs Company Profile

Crocs, Inc is a global footwear designer, developer and distributor best known for its lightweight, proprietary Croslite™ foam-clog construction. The company’s product portfolio encompasses a range of styles, including clogs, sandals, slides, boots and sneakers, all featuring the slip-resistant, odor-resistant and cushion-providing qualities of the Croslite material. Crocs distributes its products through an omnichannel network that includes e-commerce platforms, company-owned retail stores, authorized dealers and wholesale partners.

Founded in 2002 by Scott Seamans, Lyndon “Duke” Hanson and George Boedecker Jr., Crocs launched its first clog on the island of Vail, Colorado.